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ABSTRACT 
Letrozole (LTZ) is an oral non-steroidal aromatase inhibitor for the treatment of hormonally responsive breast cancer after 
surgery. The objective of the current study is to prepare and evaluate Solid lipid nanoparticles (SLN) of LTZ. SLNs were 
prepared by hot homogenization followed by ultrasonication. Trimyristin was used as solid lipid core, Soyphosphatidyl 
choline, Tween 80 as surfactant mixture. Process and formulation variables were studied and optimized. LTZ-SLN were 
characterized  for  mean  particle  size,  polydispersity  index  (PDI)  and  zeta potential  for  all  the  formulations.  The  mean 
particles size, PDI, zeta potential and entrapment efficiency of optimized LTZ-SLN optimized formulation was found to be 
28.54 nm, 0.162, 11.80 mV, 85.64 %, respectively. In vitro release profiles are performed in 0.1N HCl using modified franz 
diffusion  cell  showed  controlled  drug  release  behavior  over  a  period  of  24h.  LTZ-SLN  formulations  are  subjected  to 
stability study over a period of 1 month in terms of particle size, zeta potential, PDI, entrapment efficiency and are found to 
be stable. Differential scanning calorimetry (DSC) and transmission electron microscopy (TEM) analysis was performed to 
characterize the state of drug, lipid modification, shape and surface morphology of prepared LTZ-SLN formulations. 
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INTRODUCTION 
Solid  lipid  nanoparticles  (SLNs)  were  developed  as  an 
interesting  carrier  system  in  the  middle  of  1990s.  SLN 
combines the advantages of polymeric nanoparticles such as 
controlled  drug  release,  cytotoxicity  and  avoiding  drug 
leakage, and the advantages of emulsion and liposome such 
as  low  toxicity,  good  biocompatibility  and  higher 
bioavailability. 
[1-2] Moreover, compared with the traditional 
polymeric nanoparticles, an  outstanding advantage of solid 
lipid  nanoparticles  (SLNs)  is  that  the  lipid  matrix  is 
composed  of  physiologically  tolerated  lipid  components, 
which decreases the potential for acute and chronic toxicity. 
[3] However, there were some disadvantages for SLN namely 
limitation in drug loading capacity, risk of gelation and drug 
leakage during storage caused by lipid polymorphism, high 
water content of SLN dispersions (70-95%). 
[4-5] SLN consist 
of pure solid lipids. Due to presence of suitable lipid in SLN 
led to improved properties for drug loading, modulation of 
the drug release profile and stable drug incorporation during 
storage.  
Depending on the productive method and the composition of  
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lipid blend, different types of SLNs were obtained, i.e., the 
imperfect,  amorphous  and  multiple  components. 
[5] 
Crystalline of SLN, thereby lead to ‘highest incompatibility’ 
and higher drug loading. 
[6] SLNs are colloidal lipidic systems 
that  have  been  proposed  for  several  administration  routes, 
such  as  parenteral,  oral,  ocular  and  topical 
[6]  route  and 
providing  controlled  release  profiles  for  many  substances. 
These  carriers  are  composed  of  physiological  and 
biodegradable lipids exhibiting low systemic toxicity and low 
cytotoxicity.  Nanoparticles  are  produced  by  one  of  the 
following techniques, namely, high pressure homogenization 
[7],  microemulsion  template  technique 
[8-9],  Cold 
homogenization technique, solvent emulsification technique 
[10],  solvent  diffusion  technique 
[11],  reverse  micelle-double 
emulsion  technique 
[12],  homogenization  followed  by 
ultrasonication  technique,  Solvent  Injection  technique 
[13], 
and  a  very  recently  introduced  membrane  contractor 
technique. 
[14]  
Letrozole  was  used  as  a  model  drug  in  the  present  study. 
Letrozole  is  a  nonsteroidal  competitive  inhibitor  of  the 
aromatase  enzyme  system;  it  inhibits  the  conversion  of 
androgens  to  estrogens.  Letrozole  inhibits  the  aromatase 
enzyme  by  competitively  binding  to  the  heme  of  the 
cytochrome  P450  subunit  of  the  enzyme,  resulting  in  a 
reduction of estrogen biosynthesis in all tissues. Letrozole is 
rapidly  and  completely  absorbed  from  the  gastrointestinal 
tract and absorption is not affected by food. It is metabolized Nerella et al. / Formulation, Optimization and In vitro Characterization of Letrozole…..…… 
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slowly to an inactive metabolite resulting that absolute bio-
availability  of  oral  letrozole  is  low.  Therefore,  the 
development  of  novel  types  of  delivery  systems  which 
increases  the  oral  bioavailability  could  lead  to  significant 
advantages in the clinical use of the drug. 
The aim of the present study was to assess the feasibility of 
preparing SLNs loading LTZ by homogenization followed by 
ultrasonication technique and the physicochemical properties 
of obtained LTZ loaded SLN, such as mean particle size, zeta 
potential, drug entrapment efficiency,  in vitro  drug release 
behavior. The effects of composition of lipid materials and 
surfactant  mixture  on  particle  size,  zeta  potential,  drug 
entrapment  efficiency,  and  in  vitro  drug  release  behavior 
were investigated in detail. Differential scanning calorimetry 
(DSC) analyses were performed to investigate the status of 
the lipid and the drug. Shape and surface morphology was 
determined by TEM. 
 
MATERIALS AND METHODS 
Materials 
LTZ  was  a  kind  gift  from  NATCO  PHARMA  Pvt.  Ltd; 
Hyderabad, trimyristin (TM) (Dynasan 114) was generously 
supplied  by  Sasol  (Witten,  Germany);  Soy 
phosphatidylcholine  99%  (Epikuron  200)  was  donated  by 
Degussa Texturant Systems (Deutschland, Hamburg). Tween 
80 and dialysis membrane-70 were purchased from Hi-Media 
(Mumbai, India). Centrisart filters (molecular weight cutoff 
20,000)  were  purchased  from  Sartorius  (Goettingen, 
Germany).  The  other  chemicals  were  of  analytical  reagent 
grade.  
Preparation of LTZ loaded solid lipid nanoparticles 
LTZ,  trimyristin,  and  soy  phosphatidylcholine  99%  were 
dissolved  in  mixture  of  chloroform  and  methanol  (1:1). 
Organic  solvents  were  completely  removed  using  a 
rotaevaporator (Laborota 4000, Heidolph, Germany). Drug-
embedded lipid layer was melted by heating at 5°C above 
melting point of the lipid. An aqueous phase was prepared by 
dissolving polysorbate 80 in double distilled water (sufficient 
to  produce  10  ml  of  preparation)  and  heated  to  same 
temperature of oil phase. Hot aqueous phase was added to the 
oil  phase,  and  homogenization  was  carried  out  (at  12,000 
rpm)  using  a  Diax  900  homogenizer  (Heidolph,  Germany) 
for 3  min.  Obtained  hot oil  in  water coarse emulsion  was 
ultrasonicated  using  Sonoplus  ultrahomogenizer  (Bandelin, 
Germany)  for  15-20  min  and  allowed  to  cool  to  room 
temperature to get LTZ loaded SLNs and was stored at 4-8ºC 
for further analysis. 
Characterization  of  LTZ  loaded  Solid  Lipid 
Nanoparticles 
Measurement of particle Size and zeta potential  
The size and zeta potential of SLN were measured by photon 
correlation  spectroscopy  using  a  Zetasizer  3000  HSA 
(Malvern,  UK).  Zeta  potential  was  carried  out  at  room 
temperature and the electric field strength was around 23.4 
V/cm. Samples were diluted appropriately with the aqueous 
phase  of  the  formulation  to  get  optimum  kilo  counts  per 
second (Kcps) of 50-200 for measurements, and the pH of 
diluted samples ranged from 7.0 ± 0.2. 
Determination of drug content  
Drug content was estimated in the form of assay, 50µL of 
SLN  formulation  was  diluted  to  1  mL  with  chloroform: 
methanol (1:1). The final dilution was made with the mobile 
phase, and LTZ content was determined by HPLC.  
HPLC methodology for Letrozole 
HPLC determination of LTZ was performed using Shimadzu 
LC 20AT solvent delivery pump equipped with a 20µL loop 
and rheodyne sample injector UV-Visible detector at 230nm. 
Samples  were  chromatographed  on  a  stainless  steel  C-18 
reverse  phase  column  (250  ×  4.25  mm)  packed  with  5μm 
particle (phenomenex column).   
Determination of entrapment efficiency 
Entrapment efficiency (EE%) was determined by measuring 
the  concentration  of  free  drug  (unentrapped)  in  aqueous 
medium as reported previously Venkateswarlu et al., 2004. 
[15]  The  aqueous  medium  was  separated  by  ultra-filtration 
using  centrisart  tubes  (Sartorius,  USA),  which  consists  of 
filter membrane (M.wt. cut off 20,000 Da) at the base of the 
sample recovery chamber. About 1ml of the formulation was 
placed in the outer chamber and sample recovery chamber 
placed on top of the sample and centrifuged at 4000 rpm for 
15 min. The SLN along with encapsulated drug remained in 
the outer chamber and aqueous phase moved into the sample 
recovery chamber through filter membrane. The amount of 
LTZ in the aqueous phase was estimated by HPLC method 
and the entrapment efficiency was calculated by the equation:  
Drug entrapment efficiency (%) = analyzed weight of drug in 
SLNs / theoretical weight of drug loaded in system × 100. 
In vitro release Study 
In vitro release studies were performed in 0.1N HCl (pH 1.2) 
using  modified  franz diffusion cell and dialysis  membrane 
having pore size 2.4 nm, molecular weight cut-off between 
12,000-14,000 was used. Membrane  was  soaked in double 
distilled water for 12 h. SLN dispersion (2 mL) was placed in 
the donor compartment and  the receptor compartment  was 
filled with 50 mL of release media. During the experiments, 
the solution in receptor side was maintained at 37°C ± 0.5°C 
and stirred at 800 rpm with magnetic stirring bars. At 0.5, 1, 
2,  3,  4,  6,  8,  12,  and  24  h  time  points,  samples  were 
withdrawn and analyzed by HPLC.  Data obtained from in 
vitro release studies were fitted to various kinetic equations 
to find out the mechanism of LTZ release from SLN.  
Stability Studies 
LTZ loaded SLN was stored at room temperature (25°C) and 
at refrigerator temperature (2-8
0C) for 1 month and average 
particle  size,  zeta  potential,  PDI  were  determined.  LTZ 
loaded SLNs were stored at room temperature for 30 days 
and entrapment efficiency is calculated. 
Differential scanning calorimetry (DSC)  
DSC  analysis  of  LTZ,  TM,  physical  mixture  (PM),  and 
lyophilized  LTZ-SLN  was  performed  using  Mettler  DSC 
(Mettler-Toledo,  Viroflay,  France).  The  instrument  was 
calibrated with indium. All the samples (~5 mg) were heated 
in aluminum pans using dry nitrogen as the effluent gas. The 
analysis  was  performed  with  a  heating  range  of  30-200°C 
and at a rate of 10°C/min. Analysis was performed under a 
nitrogen purge (50 mL/min).  
Transmission Electron Micrographic studies 
Images  were  recorded  on  a  Transmission  Electron 
Micrograph (Hitachi, Japan, Model Model H. 7500 ID) with 
magnification:  179000x.  LTZ  loaded  SLN  was  diluted 
appropriately with 0.1 M phosphate buffer and centrifuged at 
4000 rpm for 5 min. Few drops of the diluted emulsion was 
placed on grid and stained with 2 % uranyl acetate, and then 
the image was captured.  
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Table 1: Composition of the investigated LTZ-SLN formulations 
Formulations  Letrozole (mg)  Trimyristin (% w/v)  Soyphosphatidylcholine (% w/v)  Tween 80 in 20 mL 
Water (%w/v) 
Solvent system (mL) 
(Chloroform & Methanol, 1:1) 
SLN 1  2.5  1.5  0.75  1.5  10 
SLN 2  2.5  1.5  0.75  1.25  10 
SLN 3  2.5  1.5  0.5  1.0  10 
SLN 4  2.5  1.5  0.5  0.75  10 
SLN 5  2.5  1.25  0.75  1.5  10 
SLN 6  2.5  1.25  0.75  1.25  10 
SLN 7  2.5  1.25  0.5  1.0  10 
SLN 8  2.5  1.25  0.5  0.75  10 
 
Table 2: Mean particle size, PDI, zeta potential and entrapment efficiency (EE%) of investigated LTZ-SLN formulations  (mean ± SD, n = 3) 
Formulation  Mean particle size (nm)  Zeta potential (mV)  PDI  Entrapment efficiency (%) 
SLN 1  28.54 ± 4.23  11.8 ± 6.62  0.162 ± 0.09  85.64 ± 6.50 
SLN 2  30.36 ± 4.95  11.4 ± 6.68  0.158 ± 0.012  84.32 ± 6.13 
SLN 3  33.86 ± 8.91  8.26 ± 6.11  0.201 ± 0.008  83.15 ± 4.96 
SLN 4  32.45 ± 4.29  7.28 ± 5.58  0.185 ± 0.021  81.74 ± 6.22 
SLN 5  32.71 ± 3.53  7.86 ± 5.61  0.189 ± 0.011  85.07 ± 5.48 
SLN 6  34.36 ± 4.47  7.44 ± 4.48  0.212 ± 0.016  84.85 ± 5.78 
SLN 7  37.10 ± 5.12  6.98 ± 3.15  0.209 ± 0.014  82.69 ± 7.66 
SLN 8  37.64 ± 7.66  6.24 ± 2.12  0.196 ± 0.025  80.97 ± 8.71 
 
Table 3: Influence of storage condition and duration of storage on Mean particle size, zeta potential and PDI of optimized SLN formulations 
Storage condition  Duration  Formulation  Zeta Size (nm)  Zeta Potential (mV)  PDI 
Room temperature 
Day 1  SLN1  28.54 ± 4.23  11.8 ± 6.62  0.162 ± 0.09 
SLN5  32.71 ± 3.53  7.86 ± 5.61  0.189 ± 0.011 
Day 30  SLN1  36.47 ± 2.52  8.14 ± 2.34  0.215 ± 0.056 
SLN5  39.13 ± 3.65  5.34 ± 4.18  0.223 ± 0.066 
Day 60  SLN1  38.37 ± 6.24  3.64 ± 2.27  0.303± 0.073 
SLN5  42.29 ± 8.46  3.31 ± 2.29  0.377± 0.028 
Refrigerator 
temperature 
Day 1  SLN1  28.54 ± 4.23  11.8 ± 6.62  0.162 ± 0.09 
SLN5  32.71 ± 3.53  7.86 ± 5.61  0.189 ± 0.011 
Day 30  SLN1  41.82 ± 4.37  6.86 ± 2.64  0.268 ± 0.058 
SLN5  45.67 ± 5.68  5.74 ± 2.25  0.307± 0.043 
Day 60  SLN1  56.27 ± 7.38  4.95 ± 1.69  0.352 ± 0.078 
SLN5  58.25 ± 7.35  3.26 ± 2.14  0.322 ± 0.054 
 
Preparation of LTZ loaded SLN 
Homogenization  followed  by  ultrasonication  is  a  reliable, 
simple  and  reproducible  method  for  preparing  SLN. 
[15-16] 
Trimyristin  as  solid  lipid,  a  mixture  of  Soy 
phosphatidylcholine 99%, and tween 80 as surfactants were 
used in the formulation. It is known that the employ of two 
surfactants, respectively of lipophilic and hydrophilic nature, 
yields  a  better  stabilization  of  the  disperse  system.  The 
solvent mixture of chloroform and methanol (1:1) was found 
to be effective in homogenously dispersing the drug in the 
lipid phase. Rota evaporation at 5°C above the melting point 
of lipid and ensured the complete removal of the traces of 
organic solvents. Homogenization of the lipid phase with hot 
aqueous  tween  80  solution  for  3-4  min  was  sufficient  to 
produce a coarse emulsion with average particle size between 
2.58 and 2.96µ. Further increase in homogenization time did 
not show any significant decrease in the particle size. Thus a 
homogenization  time  of  3-4  min  was  selected  for  all  the 
formulations and further reduction of size was preceded with 
sonication.  Sonicating  the  coarse  emulsion  for  20  min 
resulted in particles between 28 and 38 nm with narrow size 
distribution.  In  order  to  optimize  the  lipid  to  drug  ratio, 
different amounts of trimyristin (250 and 300 mg) were tried 
with  fixed  amount  of  LTZ  (2.5  mg)  and  soy 
phosphatidylcholine  99%  (100  mg  &  75  mg).  The  final 
compositions of the investigated SLN dispersions were given 
in Table 1. 
Particle sizes and zeta potentials 
All the prepared samples were analyzed in order to determine 
their particle size distributions and zeta potential values. The 
results  obtained  after  particle  size  analysis  are  shown  in 
Table 2. In all formulations, the particle sizes ranged from 28 
to 38 nm, and zeta potentials were about +6.2 mV to +11.8 
mV.  The  increasing  of  surfactant  content  in  SLNs 
formulations could reduce the interface tension between lipid 
matrix and dispersion medium (aqueous phase), consequently 
favor  the  formation  of  SLNs  with  smaller  particle  size. 
Tween 80 also provides a steric stability for maintaining the 
stability  of  SLN  (15).  To  obtain  stable  and  smaller  SLN, 
tween 80 concentrations were varied from 1.5 % to 0.75 % 
(300 to 150 mg). It is evident from the table 2, that tween 80 
concentration  of  1.5%  was  effective  in  producing  smaller 
particle size.  
Zeta  potential  is  a  key  factor  to  evaluate  the  stability  of 
colloidal  dispersion.  It  was  currently  admitted  that  zeta 
potentials  above  30mV  were  required  for  full  electrostatic 
stabilization. However, many experiments demonstrated that 
not  only  electrostatic  repulsion  dominated  the  stability  of 
nanoparticles,  the  use  of  steric  stabilizer  also  favored  the 
formation  of  stable  nanoparticle  dispersion.
  [17-18]  In  these 
studies,  it  seemed  that  the  value  of  zeta  potential  of  LTZ 
loaded  SLNs  was  not  sufficient  to  keep  the  particles 
dispersing stably. However, the particle size did not change 
significantly within 30 days, which should contribute to the 
following  point.  High  surfactant  mixture  can  easily 
compensate for missing electrostatic repulsion to stabilize the 
dispersion for long time. Tween 80 provides a steric stability 
for maintaining the stability of SLN. 
Entrapment efficiency 
Drug  expulsion  in  SLN  can  occur  when  the  lipid  matrix 
transforms from high energy modifications, characterized by 
the  presence  of  many  imperfections,  to  the  β-modification 
forming a perfect crystal with no room for guest molecules. 
This phenomenon is even more pronounced when high purity Nerella et al. / Formulation, Optimization and In vitro Characterization of Letrozole…..…… 
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lipids are used. The high purity lipid matrix of these particles 
solidifies upon cooling but does not recrystallize and remains 
in  the  amorphous  state.  A  second  type  of  SLN  is  formed 
when  the  lipid  molecules  are  chemically  very  different, 
resulting  in  a  structure  with  many  imperfections  to 
accommodate  the  drug  and  thus  higher  loading  capacity. 
About  87  %  of  entrapment  efficiency  is  seen  in  SLN  1 
formulation. As the surfactant concentration is increased in 
the formulation increase in entrapment efficiency of the SLN 
formulations were observed. Entrapment efficiency of SLN 
formulations are shown in Table 2.  
Effect of amount of surfactant mixture on particle size, 
zeta potential and PDI 
The  surfactant  amount  in  SLN  is  an  important  factor 
determining  the  physicochemical  characteristics  due  to  the 
surface-active  properties.  Whether  the  increase  in  the 
surfactant amount influenced the zeta potential, particle size 
and PDI of LTZ-SLN was investigated. As expected, the zeta 
potential of  SLNs  tended to decrease  with decrease in the 
total amount of surfactant mixture (soy phosphatidylcholine 
+  tween  80).  As  the  amount  of  surfactant  mixture  is 
increasing there is a little decrease in the particle size value. 
The  effect  of  surfactant  composition  on  the  size,  zeta 
potential and PDI of SLN are presented in figure 1. 
In vitro release Study 
In  order  to  evaluate  the  controlled  release  potential  of  the 
investigated formulations, the diffusion of LTZ from the lipid 
particles  was  investigated  over  24  h.  In  vitro  drug  release 
profile  of  LTZ  loaded  SLN  formulations  are  presented  in 
figure 2. SLN formulations, SLN 4 and 8 showed maximum 
drug release in 12 h, SLN 3 and 7 in 18 h. 
Due to low content of lipid in formulations SLN 5 to SLN 8 
showed more drug release compared to SLN formulations 1 
to 4. As the surfactant concentration is decreasing from 1.5% 
to 0.75% there is decrease in controlled release properties of 
the SLN formulations. There is high amount of drug release 
in the formulation SLN 3, 4, 7, and 8 than SLN 1, 2,  5, and 6 
due to decrease in amount of lipid concentration from 1.5 to 
1.25.  In  vitro  drug  release  profile  of  SLN  formulations  in 
0.1N HCl were shown in figure 2. The drug release data of 
most of the SLN formulations fitted well into the Higuchi 
square root release kinetics (r
2 values ranging from 0.92 to 
0.99).  This  indicates  that  the  test  product  follows  matrix 
diffusion based release kinetics. 
Stability study 
All the formulations are stored in amber colored bottles at 
room temperature and refrigerator temperature. As SLN 3, 4, 
7, and 8 formulations are not stable, so rest of formulations 
that is SLN 1, 2, 5 and 6 are analyzed for particle size, zeta 
potential  and  PDI  on  initial,  15  days  and  1  month  of 
preparation  which  are  stored  at  room  temperature  and 
refrigerator  temperature.  SLN  1,  2,  5,  6  are  analyzed  for 
entrapment  efficiency  on  initial,  15  days  and  1  month  of 
preparation which are stored at room temperature. The effect 
of duration of storage and storage condition on particle size, 
zeta potential and PDI of SLN are presented in figure 3 and 
Table 3. 
There  is  no  significant  difference  in  particle  size,  zeta 
potential, and PDI between SLN on the day of preparation 
but as the duration of storage increases up to one month the 
SLN formulation found to be stable. The good stability might 
derive from the slow transition of lipid in nano formulations, 
low particles size and the steric effect of Tween 80. These 
results  clearly  suggest  that  an  optimum  tween  80 
concentration of 1.5% was sufficient to cover the surface of 
nanoparticles  effectively  and  prevent  agglomeration  during 
the  homogenization  process.  During  long-term  storage, 
triglycerides undergo degradation to fatty acids and mono- 
and  diglycerides,  which  could  compete  with  formulation 
surfactants  for  positioning  on  the  surface.  Fatty  acids  and 
monoglycerides can form mixed micelles that might enhance 
the partitioning of hydrophobic drug out of the nanoparticle. 
Therefore,  the  concentration  of  excipients  and  possible 
degradation products need to be determined to understand the 
stability of nanoparticles. The effect of duration of storage 
and  storage  condition  at  room  temperature  on  entrapment 
efficiency  of  LTZ-SLN  is  presented  in  figure  4.  As  the 
duration of storage increased the entrapment efficiency was 
found to be decreased. 
 
Fig. 1: Effect of surfactant composition on the size, zeta potential and 
PDI of all the SLN formulations 
 
Fig. 2: In vitro drug release profile of SLN formulations in 0.1 N HCl 
(pH 1.2) Nerella et al. / Formulation, Optimization and In vitro Characterization of Letrozole…..…… 
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Fig. 3:  Influence of storage condition and duration of storage on size 
and zeta potential and PDI of optimized SLN (SLN1) formulation 
 
Fig. 4: Influence of duration of storage and storage condition at room 
temperature on entrapment efficiency of optimized SLN (SLN1, 2, 5 & 
6) formulations 
 
Fig. 5: DSC thermograms of LTZ (A), trimyristin (B), physical mixture 
of LTZ and TM (C), and lyophilized LTZ-SLN (D) 
 
Fig.  6:  Transmission  electron  microscope  image  of  optimized  LTZ 
loaded SLN 
 
DSC Analysis 
DSC thermograms of LTZ, trimyristin, physical mixture of 
drug and lipid, LTZ-SLN optimized formulation are shown 
in  figure  5.  The  melting  endotherm  of  the  drug  was 
completely absent in the thermograms of LTZ loaded SLN, 
which indicates that LTZ was completely solubilized inside 
the lipid matrix of the SLN. Incorporation of LTZ inside the 
lipid matrix results in an increase in the number of defects in 
the lipid crystal lattice, and hence causes a decrease in the 
melting  point  of  the  lipid  in  the  final  SLN  formulations. 
LTZ-SLN  was  prepared  and  characterized  for  comparison 
with  physical  mixture  and  individual  excipients.  Bulk 
trimyristin showed a sharp endothermic event, ascribing to 
the melting, (minimum) around 58.68°C with an extrapolated 
onset of the melting peak 53.28°C (the difference between 
onset and minimum can be taken as a measure for the width 
of  the  peak).  When  the  raw  material  was  formulated  as 
nanoparticles, the endothermic happened at a slightly lower 
temperature. These differences are generally ascribed to the 
nanometric size of the particles, having then a high specific 
surface area.
 [19] A certain effect due to the surfactant should 
be taken into account as well in the formulation. 
[20]  
Visualization  by  Transmission  Electron  Microscopy 
(TEM) 
The result of TEM imaging of LTZ loaded SLN are shown in 
figure 6 indicating that the particles are nanometer in size, 
spherical shapes and no drug crystal (irregular crystallization 
with the vast majority of needle or rod crystal in the length 
range from 10 micron to a few dozen microns) was visible. 
The average particle size of optimized LTZ loaded SLN was 
found to be 28.45 nm. 
 
The results of the prepared LTZ loaded SLNs revealed that 
SLNs are potential carriers systems for LTZ for the effective 
management  of  hormonally  responsive  breast  cancer  after 
surgery.  In  vitro  drug  release  profiles  and  entrapment 
efficiency were depending on the concentration of the lipid 
and surfactant mixture employed. The release rate of the LTZ 
was  decreases  with  a  higher  lipid  concentration,  which  is 
explained by the physical morphology of the lipid particles. 
After 1 month of storage at different temperatures the mean 
diameters  of  SLN  remain  practically  the  same,  which 
emphasizes the physical stability of these prepared solid lipid Nerella et al. / Formulation, Optimization and In vitro Characterization of Letrozole…..…… 
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nanoparticles. Fairly spherical shaped, stable and controlled 
release  LTZ  loaded  SLN  could  be  prepared  by  hot 
homogenization followed by ultrasonication technique. 
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